PEPGEN INC. Retained Earnings
PEPGEN INC. (PEPG) had Retained Earnings of -$396.69 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$396.69M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$378.88M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$361.12M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$342.78M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$396.69M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$378.88M 10-Q · filed 2026-05-12 |
| 2025-12-31 | -$361.12M 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$342.78M 10-Q · filed 2025-11-12 |
| 2025-06-30 | -$324.75M 10-Q · filed 2025-08-07 |
| 2025-03-31 | -$301.67M 10-Q · filed 2025-05-08 |
| 2024-12-31 | -$271.46M 10-K · filed 2026-03-04 |
| 2024-09-30 | -$249.22M 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$227.84M 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$199.50M 10-Q · filed 2024-05-14 |
| 2023-12-31 | -$181.48M 10-K · filed 2025-02-24 |
| 2023-09-30 | -$161.99M 10-Q · filed 2023-11-08 |
| 2023-06-30 | -$138.70M 10-Q · filed 2023-08-08 |
| 2023-03-31 | -$119.17M 10-Q · filed 2023-05-11 |
| 2022-12-31 | -$102.86M 10-K/A · filed 2024-03-29 |
| 2022-09-30 | -$87.92M 10-Q · filed 2022-11-10 |
| 2022-06-30 | -$69.31M 10-Q · filed 2022-08-12 |
| 2022-03-31 | -$52.00M 10-Q · filed 2022-06-16 |
| 2021-12-31 | -$33.75M 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |